Boundless Bio Stock

Boundless Bio is a precision oncology company developing therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers.

Sign up today and learn more about Boundless Bio Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Boundless Bio Stock

Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat intraceable cancers. It aims to be the foremost biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.

Funding History

September 2019$46.4M
April 2021$105M

Management

Chief Executive Officer & President

Zachary Hornby

Director and Co-Founder

Benjamin Cravatt

Chairman & Co-Founder

Jonathan Lim

Chief Technology Officer

Jason Christiansen

VP, Precision Medicine

Peter Krein

Board Member

Jakob Loven

Co-Founder

Keith Lenden

VP, Program Team Leadership and Strategic Alliances

Amy Berkley

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo